NovoCure Ltd

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($131.8m) ($61.7m) ($63.6m) ($7.2m) $19.8m ($58.4m) ($92.5m) ($207.0m) ($168.6m) ($136.2m)
Net Income (Loss) Available to Common Stockholders, Basic ($131.8m) ($61.7m) ($63.6m) ($7.2m) $19.8m ($58.4m) ($92.5m) ($207.0m) ($168.6m) ($136.2m)
Depreciation and amortization $5.7m $7.7m $9.0m $8.5m $9.2m $10.3m $10.6m $11.0m $11.2m $14.7m
Depreciation $1.7m $2.0m $2.0m $2.1m $2.6m $2.8m $3.1m $3.9m $6.2m $9.4m
Amortization of Debt Issuance Costs $667k $1.1m $2.8m $156k
Amortization of Debt Issuance Costs and Discounts $4.5m $3.3m $3.3m $3.3m $2.6m $3.6m
Capitalized Computer Software, Amortization $731k $1.2m $1.5m $1.7m $1.4m $1.1m $1.1m $1.3m $1.4m $1.5m
Deferred Income Tax Expense (Benefit) $17k ($354k) $348k $144k $0 $0 $0 $0 $0 $0
Share-based Payment Arrangement, Noncash Expense $22.1m $27.1m $39.8m $52.4m $75.7m $94.9m $107.0m $115.6m $160.0m $104.8m
Share-based Payment Arrangement, Expense $21.4m $27.1m $39.8m $52.4m $75.7m $94.9m $107.0m $115.6m $160.0m $104.8m
Income Tax Expense (Benefit) $10.4m $13.2m $17.6m ($1.6m) ($1.7m) $6.3m $10.7m $15.3m $37.5m ($23k)
Operating Lease, Expense $6.0m $7.3m $7.1m $8.2m $9.2m $12.0m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $6.3m $23.2m $4.2m $36.5m $30.4m ($5.3m) ($2.5m) ($29.4m) ($26.4m) ($38.9m)
Increase (Decrease) in Inventories $12.0m ($3.5m) $529k $1.2m $2.9m ($2.5m) $4.3m $8.9m ($2.6m) $5.7m
Proceeds from Stock Options Exercised $18.5m $59.2m $28.4m $21.2m $10.3m $11.4m $2.2m $6.1m
Foreign Currency Transaction Gain (Loss), before Tax $0 $0 $917k $699k ($3.2m) $3.3m ($161k) $227k ($1.3m)
General and Administrative Expense $51.0m $59.1m $73.5m $87.9m $107.4m $126.1m $132.8m $164.1m $189.8m $177.7m
Inventory Write-down $774k $489k $684k $310k $616k $1.0m $917k $681k $756k $5.7m
Investment Income, Interest $659k $1.1m $2.7m $4.4m $1.8m $791k $11.0m $19.6m $22.7m $12.9m
Operating Expenses $151.9m $160.7m $201.7m $263.6m $357.5m $464.5m $512.5m $613.9m $638.5m $642.3m
Pension Cost (Reversal of Cost) $529k $1.0m $882k $984k $1.6m $1.5m $2.1m $2.7m $3.9m $3.9m
Restructuring Costs $6.2m $2.0m $0
Net Cash Provided by (Used in) Operating Activities ($107.6m) ($33.1m) ($1.9m) $26.6m $99.1m $82.8m $30.8m ($73.3m) ($26.4m) ($49.0m)
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $5.7m $2.5m $2.9m $10.5m $15.0m $24.2m $21.4m $27.1m $42.9m $26.6m
Net Cash Provided by (Used in) Investing Activities $12.8m $6.8m ($5.5m) ($51.7m) ($472.8m) ($144.8m) ($140.0m) $184.1m ($140.2m) $437.3m
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $72.9m $149.2m $0 $558.4m $96.9m $100.0m
Repayments of Long-term Debt $100.0m $31k $150.0m $26k $28k $10k $12.9m $560.9m
Proceeds from Issuance of Common Stock $616k $1.5m $1.8m $2.5m $3.4m $4.5m $5.2m $4.4m $4.2m $3.7m
Dividends paid $0 $0
Net Cash Provided by (Used in) Financing Activities $75.1m $5.2m $69.4m $61.7m $440.2m $25.7m $15.5m $15.8m $90.3m ($451.3m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10k $8k $27k $26k $247k ($188k) ($97k) $131k ($174k) $394k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10k $8k $27k $36.7m $66.8m ($36.6m) ($93.8m) $126.7m ($76.5m) ($62.7m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10k $8k $142.8m $179.4m $246.2m $209.6m $115.8m $242.6m $166.1m $103.4m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $6.6m $10.2m $13.3m $13.7m $8.7m $101k $41k $6k $7.7m $13.4m
Income Taxes Paid, Net $9.4m $10.3m $20.4m $11.2m ($3.3m) $3.1m $5.5m $13.7m $23.5m $30.7m